25 XP   0   0   10

Vivoryon Therapeutics NV
Buy, Hold or Sell?

Let's analyse Vivoryon together

PenkeI guess you are interested in Vivoryon Therapeutics NV. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of Vivoryon Therapeutics NV. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

You can find me behind Let's Analyse Together in the top-right of each section.

Get notifications about Vivoryon Therapeutics NV

I send you an email if I find something interesting about Vivoryon Therapeutics NV.

Quick analysis of Vivoryon (30 sec.)










What can you expect buying and holding a share of Vivoryon? (30 sec.)

How much money do you get?

How much money do you get?
€0.00
When do you have the money?
1 year
How often do you get paid?
0.0%

What is your share worth?

Current worth
€1.60
Expected worth in 1 year
€2.23
How sure are you?
33.3%

+ What do you gain per year?

Total Gains per Share
€0.63
Return On Investment
116.2%

For what price can you sell your share?

Current Price per Share
€0.54
Expected price per share
€0.49 - €6.86
How sure are you?
50%

1. Valuation of Vivoryon (5 min.)




Live pricePrice per Share (EOD)

€0.54

Intrinsic Value Per Share

€-18.57 - €-22.02

Total Value Per Share

€-16.97 - €-20.42

2. Growth of Vivoryon (5 min.)




Is Vivoryon growing?

Current yearPrevious yearGrowGrow %
How rich?$44.9m$19.9m$12.4m38.4%

How much money is Vivoryon making?

Current yearPrevious yearGrowGrow %
Making money-$7.1m-$3.6m-$3.4m-48.4%
Net Profit Margin0.0%0.0%--

How much money comes from the company's main activities?

3. Financial Health of Vivoryon (5 min.)




4. Comparing to competitors in the Biotechnology industry (5 min.)




  Industry Rankings (Biotechnology)  


Richest
#556 / 1031

Most Revenue
#823 / 1031

Most Profit
#835 / 1031

Most Efficient
#277 / 1031

What can you expect buying and holding a share of Vivoryon? (5 min.)

Welcome investor! Vivoryon's management wants to use your money to grow the business. In return you get a share of Vivoryon.

What can you expect buying and holding a share of Vivoryon?

First you should know what it really means to hold a share of Vivoryon. And how you can make/lose money.

Speculation

The Price per Share of Vivoryon is €0.54. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Vivoryon.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Vivoryon, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is €1.60. Based on the TTM, the Book Value Change Per Share is €0.16 per quarter. Based on the YOY, the Book Value Change Per Share is €0.09 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is €0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Vivoryon.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 % of Price per Share% of Price per Share% of Price per Share% of Price per Share% of Price per Share
Usd Eps-0.22-41.3%-0.27-50.7%-0.14-26.2%-0.20-36.3%-0.20-36.3%
Usd Book Value Change Per Share0.63116.0%0.1731.4%0.1018.8%0.1221.4%0.1221.4%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%
Usd Total Gains Per Share0.63116.0%0.1731.4%0.1018.8%0.1221.4%0.1221.4%
Usd Price Per Share13.35-12.76-15.30-11.82-11.82-
Price to Earnings Ratio-14.95--12.44--4.20--10.10--10.10-
Price-to-Total Gains Ratio21.32-116.23-238.83-78.76-78.76-
Price to Book Ratio7.71-10.57-21.61-13.00-13.00-
Price-to-Total Gains Ratio21.32-116.23-238.83-78.76-78.76-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share0.584118
Number of shares1711
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share0.170.12
Usd Total Gains Per Share0.170.12
Gains per Quarter (1711 shares)290.45197.39
Gains per Year (1711 shares)1,161.79789.57
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
10116211520790780
2023242314015791570
3034853476023692360
4046474638031583150
5058095800039483940
6069716962047374730
7081338124055275520
8092949286063176310
901045610448071067100
1001161811610078967890

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share0.04.00.00.0%1.011.00.08.3%1.014.00.06.7%1.014.00.06.7%1.014.00.06.7%
Book Value Change Per Share2.00.02.050.0%4.02.06.033.3%5.03.07.033.3%5.03.07.033.3%5.03.07.033.3%
Dividend per Share0.00.04.00.0%0.00.012.00.0%0.00.015.00.0%0.00.015.00.0%0.00.015.00.0%
Total Gains per Share2.00.02.050.0%4.02.06.033.3%5.03.07.033.3%5.03.07.033.3%5.03.07.033.3%

Fundamentals of Vivoryon

About Vivoryon Therapeutics NV

Vivoryon Therapeutics N.V., a clinical stage biopharmaceutical company, engages in the research, development, and commercialize small molecule-based medicines. Its pipeline products target toxic pyroglutamate-Abeta (pGlu-Abeta), which inhibits the production of pGlu-Abeta. The company's lead product candidate is PQ912, a nanomolar QPCT inhibitor that has completed Phase IIb clinical trials for use in the treatment of Alzheimer's disease. In addition, the company is developing a monoclonal antibody PBD-C06 is for N3pE-Abeta. Vivoryon Therapeutics N.V. has a collaboration agreement with Nordic Bioscience for the clinical development of PQ912 for Alzheimer's disease; and research collaboration with the Fraunhofer Institute for cell therapy and immunology, as well as a strategic regional licensing partnership with Simcere Pharmaceutical Group Ltd. to develop and commercialize medicines targeting the neurotoxic amyloid species N3pE (pGlu-Abeta) to treat Alzheimer's disease. Vivoryon Therapeutics N.V. was founded in 1997 and is headquartered in Halle, Germany.

Fundamental data was last updated by Penke on 2024-03-19 05:20:05.

Financial Health

Profitability Details
 Compared to previous yearCompared to industry
Using its assets, the company is very inefficient in making profit.
Using its investors money, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
Liquidity Details
 Compared to previous yearCompared to industry
The company is very able to pay all its short-term debts.
The company is very able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is very able to pay all its debts by selling its assets.
The company is very able to pay all its debts with equity.

Valuation

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is expensive.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.

1.1. Profitability of Vivoryon Therapeutics NV.

1.1. Profitability
1.1.1. Net Profit Margin

Measures how much net profit Vivoryon earns for each €1 of revenue.

  • Above 10% is considered healthy but always compare Vivoryon to the Biotechnology industry mean.
  • A Net Profit Margin of 0.0% means that €0.00 for each €1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Vivoryon Therapeutics NV:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.0%
TTM-YOY-0.0%
TTM-5Y-0.0%
5Y-10Y-0.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--171.8%+171.8%
TTM--205.8%+205.8%
YOY--262.1%+262.1%
5Y--455.6%+455.6%
10Y--589.0%+589.0%
1.1.2. Return on Assets

Shows how efficient Vivoryon is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Vivoryon to the Biotechnology industry mean.
  • -11.8% Return on Assets means that Vivoryon generated €-0.12 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Vivoryon Therapeutics NV:

  • The MRQ is -11.8%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -19.6%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-11.8%TTM-19.6%+7.7%
TTM-19.6%YOY-12.1%-7.5%
TTM-19.6%5Y-14.8%-4.7%
5Y-14.8%10Y-14.8%0.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-11.8%-12.5%+0.7%
TTM-19.6%-12.2%-7.4%
YOY-12.1%-11.2%-0.9%
5Y-14.8%-13.4%-1.4%
10Y-14.8%-14.7%-0.1%
1.1.3. Return on Equity

Shows how efficient Vivoryon is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Vivoryon to the Biotechnology industry mean.
  • -12.9% Return on Equity means Vivoryon generated €-0.13 for each €1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Vivoryon Therapeutics NV:

  • The MRQ is -12.9%. Using its investors money, the company is very inefficient in making profit. -2
  • The TTM is -23.3%. Using its investors money, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-12.9%TTM-23.3%+10.4%
TTM-23.3%YOY-16.8%-6.6%
TTM-23.3%5Y-18.4%-5.0%
5Y-18.4%10Y-18.4%0.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-12.9%-15.8%+2.9%
TTM-23.3%-15.7%-7.6%
YOY-16.8%-13.9%-2.9%
5Y-18.4%-18.3%-0.1%
10Y-18.4%-19.2%+0.8%

1.2. Operating Efficiency of Vivoryon Therapeutics NV.

1.2. Operating Efficiency
1.2.1. Operating Margin

Measures how efficient Vivoryon is operating .

  • Measures how much profit Vivoryon makes for each €1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Vivoryon to the Biotechnology industry mean.
  • An Operating Margin of 0.0% means the company generated €0.00  for each €1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Vivoryon Therapeutics NV:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.0%
TTM-YOY-0.0%
TTM-5Y-0.0%
5Y-10Y-0.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--299.1%+299.1%
TTM--210.1%+210.1%
YOY--279.7%+279.7%
5Y--459.9%+459.9%
10Y--596.9%+596.9%
1.2.2. Operating Ratio

Measures how efficient Vivoryon is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Biotechnology industry mean).
  • An Operation Ratio of 0.00 means that the operating costs are €0.00 for each €1 in net sales.

Let's take a look of the Operating Ratio trends of Vivoryon Therapeutics NV:

  • The MRQ is 0.000. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.000
TTM-YOY-0.000
TTM-5Y-0.000
5Y-10Y-0.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-2.861-2.861
TTM-3.193-3.193
YOY-3.615-3.615
5Y-5.560-5.560
10Y-7.396-7.396

1.3. Liquidity of Vivoryon Therapeutics NV.

1.3. Liquidity
1.3.1. Current Ratio

Measures if Vivoryon is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Biotechnology industry mean).
  • A Current Ratio of 19.45 means the company has €19.45 in assets for each €1 in short-term debts.

Let's take a look of the Current Ratio trends of Vivoryon Therapeutics NV:

  • The MRQ is 19.453. The company is very able to pay all its short-term debts. +2
  • The TTM is 14.427. The company is very able to pay all its short-term debts. +2
Trends
Current periodCompared to+/- 
MRQ19.453TTM14.427+5.026
TTM14.427YOY5.675+8.752
TTM14.4275Y20.060-5.633
5Y20.06010Y20.0600.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ19.4533.986+15.467
TTM14.4274.440+9.987
YOY5.6755.552+0.123
5Y20.0606.158+13.902
10Y20.0606.492+13.568
1.3.2. Quick Ratio

Measures if Vivoryon is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Vivoryon to the Biotechnology industry mean.
  • A Quick Ratio of 7.19 means the company can pay off €7.19 for each €1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Vivoryon Therapeutics NV:

  • The MRQ is 7.186. The company is very able to pay all its short-term debts with the most liquid assets. +2
  • The TTM is 2.820. The company is very able to pay all its short-term debts with the most liquid assets. +2
Trends
Current periodCompared to+/- 
MRQ7.186TTM2.820+4.366
TTM2.820YOY0.640+2.181
TTM2.8205Y4.362-1.542
5Y4.36210Y4.3620.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ7.1863.638+3.548
TTM2.8204.168-1.348
YOY0.6405.515-4.875
5Y4.3626.012-1.650
10Y4.3626.209-1.847

1.4. Solvency of Vivoryon Therapeutics NV.

1.3. Liquidity
1.4.1. Debt to Asset Ratio

Measures how much % of Vivoryon assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Vivoryon to Biotechnology industry mean.
  • A Debt to Asset Ratio of 0.08 means that Vivoryon assets are financed with 8.4% credit (debt) and the remaining percentage (100% - 8.4%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Vivoryon Therapeutics NV:

  • The MRQ is 0.084. The company is very able to pay all its debts by selling its assets. +2
  • The TTM is 0.150. The company is very able to pay all its debts by selling its assets. +2
Trends
Current periodCompared to+/- 
MRQ0.084TTM0.150-0.066
TTM0.150YOY0.296-0.146
TTM0.1505Y0.176-0.026
5Y0.17610Y0.1760.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.0840.335-0.251
TTM0.1500.330-0.180
YOY0.2960.267+0.029
5Y0.1760.367-0.191
10Y0.1760.378-0.202
1.4.2. Debt to Equity Ratio

Measures if Vivoryon is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Vivoryon to the Biotechnology industry mean.
  • A Debt to Equity ratio of 9.2% means that company has €0.09 debt for each €1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Vivoryon Therapeutics NV:

  • The MRQ is 0.092. The company is very able to pay all its debts with equity. +2
  • The TTM is 0.179. The company is very able to pay all its debts with equity. +2
Trends
Current periodCompared to+/- 
MRQ0.092TTM0.179-0.087
TTM0.179YOY0.427-0.248
TTM0.1795Y0.233-0.054
5Y0.23310Y0.2330.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.0920.376-0.284
TTM0.1790.398-0.219
YOY0.4270.334+0.093
5Y0.2330.429-0.196
10Y0.2330.476-0.243

2. Market Valuation of Vivoryon Therapeutics NV

2.1. Earnings Per Share
2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every €1 in earnings Vivoryon generates.

  • Above 15 is considered overpriced but always compare Vivoryon to the Biotechnology industry mean.
  • A PE ratio of -14.95 means the investor is paying €-14.95 for every €1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Vivoryon Therapeutics NV:

  • The EOD is -0.654. Based on the earnings, the company is expensive. -2
  • The MRQ is -14.948. Based on the earnings, the company is expensive. -2
  • The TTM is -12.439. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-0.654MRQ-14.948+14.294
MRQ-14.948TTM-12.439-2.510
TTM-12.439YOY-4.200-8.239
TTM-12.4395Y-10.103-2.336
5Y-10.10310Y-10.1030.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-0.654-2.643+1.989
MRQ-14.948-2.418-12.530
TTM-12.439-2.742-9.697
YOY-4.200-4.123-0.077
5Y-10.103-6.257-3.846
10Y-10.103-6.478-3.625
2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Vivoryon Therapeutics NV:

  • The EOD is -0.345. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -7.894. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is -9.908. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-0.345MRQ-7.894+7.549
MRQ-7.894TTM-9.908+2.014
TTM-9.908YOY-50.398+40.490
TTM-9.9085Y-23.522+13.614
5Y-23.52210Y-23.5220.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-0.345-3.244+2.899
MRQ-7.894-2.939-4.955
TTM-9.908-3.478-6.430
YOY-50.398-5.592-44.806
5Y-23.522-8.473-15.049
10Y-23.522-8.881-14.641
2. Book Value per Share
2.3. Price to Book Ratio

Measures if the stock price of Vivoryon is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Biotechnology industry mean).
  • A PB ratio of 7.71 means the investor is paying €7.71 for each €1 in book value.

Let's take a look of the Price to Book Ratio trends of Vivoryon Therapeutics NV:

  • The EOD is 0.338. Based on the equity, the company is cheap. +2
  • The MRQ is 7.713. Based on the equity, the company is overpriced. -1
  • The TTM is 10.574. Based on the equity, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD0.338MRQ7.713-7.376
MRQ7.713TTM10.574-2.860
TTM10.574YOY21.607-11.034
TTM10.5745Y13.002-2.428
5Y13.00210Y13.0020.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD0.3382.124-1.786
MRQ7.7132.041+5.672
TTM10.5742.118+8.456
YOY21.6072.915+18.692
5Y13.0023.682+9.320
10Y13.0024.114+8.888
2. Total Gains per Share

3. Summary

3.1. Key Performance Indicators

The key performance indicators of Vivoryon Therapeutics NV compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share--0.5790.157+269%0.094+516%0.107+443%0.107+443%
Book Value Per Share--1.6001.153+39%0.711+125%1.071+49%1.071+49%
Current Ratio--19.45314.427+35%5.675+243%20.060-3%20.060-3%
Debt To Asset Ratio--0.0840.150-44%0.296-72%0.176-52%0.176-52%
Debt To Equity Ratio--0.0920.179-49%0.427-78%0.233-61%0.233-61%
Dividend Per Share----0%-0%-0%-0%
Eps---0.206-0.253+23%-0.131-37%-0.181-12%-0.181-12%
Free Cash Flow Per Share---0.391-0.307-22%-0.144-63%-0.186-52%-0.186-52%
Free Cash Flow To Equity Per Share--0.0600.051+16%0.037+62%0.011+469%0.011+469%
Gross Profit Margin--1.0001.0000%1.0000%1.0000%1.0000%
Intrinsic Value_10Y_max---22.023--------
Intrinsic Value_10Y_min---18.569--------
Intrinsic Value_1Y_max---1.004--------
Intrinsic Value_1Y_min---0.986--------
Intrinsic Value_3Y_max---3.933--------
Intrinsic Value_3Y_min---3.737--------
Intrinsic Value_5Y_max---7.968--------
Intrinsic Value_5Y_min---7.317--------
Market Cap14019426.000-2185%320369846.000306220610.500+5%367101266.000-13%283806836.833+13%283806836.833+13%
Net Profit Margin----0%-0%-0%-0%
Operating Margin----0%-0%-0%-0%
Operating Ratio----0%-0%-0%-0%
Pb Ratio0.338-2185%7.71310.574-27%21.607-64%13.002-41%13.002-41%
Pe Ratio-0.654+96%-14.948-12.439-17%-4.200-72%-10.103-32%-10.103-32%
Price Per Share0.540-2185%12.34011.795+5%14.140-13%10.932+13%10.932+13%
Price To Free Cash Flow Ratio-0.345+96%-7.894-9.908+26%-50.398+538%-23.522+198%-23.522+198%
Price To Total Gains Ratio0.933-2185%21.318116.225-82%238.832-91%78.757-73%78.757-73%
Quick Ratio--7.1862.820+155%0.640+1024%4.362+65%4.362+65%
Return On Assets---0.118-0.196+66%-0.121+2%-0.148+25%-0.148+25%
Return On Equity---0.129-0.233+81%-0.168+30%-0.184+43%-0.184+43%
Total Gains Per Share--0.5790.157+269%0.094+516%0.107+443%0.107+443%
Usd Book Value--44927327.80032392317.775+39%19963314.350+125%30071115.773+49%30071115.773+49%
Usd Book Value Change Per Share--0.6260.170+269%0.102+516%0.115+443%0.115+443%
Usd Book Value Per Share--1.7311.248+39%0.769+125%1.158+49%1.158+49%
Usd Dividend Per Share----0%-0%-0%-0%
Usd Eps---0.223-0.274+23%-0.141-37%-0.196-12%-0.196-12%
Usd Free Cash Flow---10974928.200-8615199.650-22%-4045828.425-63%-5236978.437-52%-5236978.437-52%
Usd Free Cash Flow Per Share---0.423-0.332-22%-0.156-63%-0.202-52%-0.202-52%
Usd Free Cash Flow To Equity Per Share--0.0650.056+16%0.040+62%0.011+469%0.011+469%
Usd Market Cap15164813.104-2185%346544062.418331238834.378+5%397093439.432-13%306993855.403+13%306993855.403+13%
Usd Price Per Share0.584-2185%13.34812.759+5%15.295-13%11.825+13%11.825+13%
Usd Profit---5795748.600-7109202.825+23%-3668855.975-37%-5088821.593-12%-5088821.593-12%
Usd Revenue----0%-0%-0%-0%
Usd Total Gains Per Share--0.6260.170+269%0.102+516%0.115+443%0.115+443%
 EOD+2 -6MRQTTM+23 -6YOY+18 -115Y+19 -1010Y+19 -10

3.2. Fundamental Score

Let's check the fundamental score of Vivoryon Therapeutics NV based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-0.654
Price to Book Ratio (EOD)Between0-10.338
Net Profit Margin (MRQ)Greater than00.000
Operating Margin (MRQ)Greater than00.000
Quick Ratio (MRQ)Greater than17.186
Current Ratio (MRQ)Greater than119.453
Debt to Asset Ratio (MRQ)Less than10.084
Debt to Equity Ratio (MRQ)Less than10.092
Return on Equity (MRQ)Greater than0.15-0.129
Return on Assets (MRQ)Greater than0.05-0.118
Total5/10 (50.0%)

3.3. Technical Score

Let's check the technical score of Vivoryon Therapeutics NV based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5010.930
Ma 20Greater thanMa 500.980
Ma 50Greater thanMa 1005.699
Ma 100Greater thanMa 2006.762
OpenGreater thanClose0.524
Total0/5 (0.0%)



Latest Balance Sheet

Balance Sheet of 2023-06-30. Currency in EUR. All numbers in thousands.

Summary
Total Assets45,355
Total Liabilities3,821
Total Stockholder Equity41,534
 As reported
Total Liabilities 3,821
Total Stockholder Equity+ 41,534
Total Assets = 45,355

Assets

Total Assets45,355
Total Current Assets44,742
Long-term Assets613
Total Current Assets
Cash And Cash Equivalents 29,582
Short-term Investments 12,700
Net Receivables 3,827
Total Current Assets  (as reported)44,742
Total Current Assets  (calculated)46,109
+/- 1,367
Long-term Assets
Property Plant Equipment 126
Other Assets 14
Long-term Assets  (as reported)613
Long-term Assets  (calculated)140
+/- 473

Liabilities & Shareholders' Equity

Total Current Liabilities2,300
Long-term Liabilities1,521
Total Stockholder Equity41,534
Total Current Liabilities
Accounts payable 1,291
Other Current Liabilities 691
Total Current Liabilities  (as reported)2,300
Total Current Liabilities  (calculated)1,982
+/- 318
Long-term Liabilities
Other Liabilities 1,511
Long-term Liabilities  (as reported)1,521
Long-term Liabilities  (calculated)1,511
+/- 10
Total Stockholder Equity
Common Stock25,962
Other Stockholders Equity 11,772
Total Stockholder Equity (as reported)41,534
Total Stockholder Equity (calculated)37,734
+/- 3,800
Other
Capital Stock25,962
Common Stock Shares Outstanding 25,962
Net Invested Capital 41,534
Net Tangible Assets 41,061
Net Working Capital 42,441
Property Plant and Equipment Gross 126



Balance Sheet

Currency in EUR. All numbers in thousands.

 Trend2023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-30
> Total Assets 
0
45,861
0
37,900
0
29,751
0
23,041
0
24,520
0
31,743
0
31,378
0
45,355
45,355031,378031,743024,520023,041029,751037,900045,8610
   > Total Current Assets 
45,377
45,377
36,910
36,910
28,793
28,793
22,130
22,130
28,513
20,229
30,990
30,990
30,694
30,694
44,742
44,742
44,74244,74230,69430,69430,99030,99020,22928,51322,13022,13028,79328,79336,91036,91045,37745,377
       Cash And Cash Equivalents 
0
41,524
0
3,623
0
26,306
0
19,832
0
14,661
0
24,383
0
26,555
0
29,582
29,582026,555024,383014,661019,832026,30603,623041,5240
       Short-term Investments 
0
0
0
30,848
0
0
0
667
0
7
0
7
0
7
0
12,700
12,700070707066700030,848000
       Net Receivables 
602
602
114
114
129
129
474
474
0
3,360
4,141
4,141
3,965
3,965
3,827
3,827
3,8273,8273,9653,9654,1414,1413,3600474474129129114114602602
       Other Current Assets 
21
21
1,994
1,994
21
21
675
675
8,652
1,888
2,231
2,231
174
174
61
61
61611741742,2312,2311,8888,65267567521211,9941,9942121
   > Long-term Assets 
0
484
0
989
0
958
0
910
0
4,291
0
753
0
684
0
613
6130684075304,29109100958098904840
       Property Plant Equipment 
465
465
422
422
390
390
343
343
315
285
227
227
176
176
126
126
126126176176227227285315343343390390422422465465
       Intangible Assets 
0
16
0
0
0
565
0
0
0
533
0
0
0
494
0
0
00494000533000565000160
       Other Assets 
0
0
1
1
3
3
15
15
14
3,473
14
14
14
14
14
14
1414141414143,473141515331100
> Total Liabilities 
0
3,196
0
2,825
0
3,530
0
7,570
0
7,963
0
6,506
0
4,872
0
3,821
3,82104,87206,50607,96307,57003,53002,82503,1960
   > Total Current Liabilities 
930
930
616
616
1,325
1,325
5,271
5,271
6,263
5,051
4,382
4,382
3,265
3,265
2,300
2,300
2,3002,3003,2653,2654,3824,3825,0516,2635,2715,2711,3251,325616616930930
       Accounts payable 
539
539
346
346
911
911
4,988
4,988
5,284
4,360
3,681
3,681
2,543
2,543
1,291
1,291
1,2911,2912,5432,5433,6813,6814,3605,2844,9884,988911911346346539539
       Other Current Liabilities 
62
62
131
131
147
147
192
192
887
366
444
444
381
381
691
691
6916913813814444443668871921921471471311316262
   > Long-term Liabilities 
0
2,266
0
2,209
0
2,205
0
2,299
0
2,912
0
2,124
0
1,607
0
1,521
1,52101,60702,12402,91202,29902,20502,20902,2660
       Capital Lease Obligations Min Short Term Debt
0
406
0
360
0
314
0
270
0
224
0
179
0
132
0
85
8501320179022402700314036004060
       Long-term Liabilities Other 
0
0
0
1
0
0
0
0
0
513
0
0
0
0
0
0
000000513000001000
> Total Stockholder Equity
0
42,665
0
35,075
0
26,221
0
15,471
0
16,557
0
25,237
0
26,506
0
41,534
41,534026,506025,237016,557015,471026,221035,075042,6650
   Common Stock
19,975
19,975
19,975
19,975
19,975
19,975
19,975
19,975
20,020
20,050
22,050
22,050
24,105
24,105
25,962
25,962
25,96225,96224,10524,10522,05022,05020,05020,02019,97519,97519,97519,97519,97519,97519,97519,975
   Retained Earnings Total Equity0000000000000000
   Accumulated Other Comprehensive Income 0000000000000000
   Capital Surplus 0000000000000000
   Treasury Stock0000000000000000
   Other Stockholders Equity 
-562
-562
-582
-582
3,749
3,749
4,669
4,669
5,222
6,168
6,889
6,889
9,476
9,476
11,772
11,772
11,77211,7729,4769,4766,8896,8896,1685,2224,6694,6693,7493,749-582-582-562-562



Balance Sheet

Currency in EUR. All numbers in thousands.




Cash Flow

Currency in EUR. All numbers in thousands.




Income Statement

Currency in EUR. All numbers in thousands.


Latest Income Statement (annual, 2022-12-31)

Gross Profit (+$)
totalRevenue0
Cost of Revenue-0
Gross Profit00
 
Operating Income (+$)
Gross Profit0
Operating Expense-29,059
Operating Income-29,059-29,059
 
Operating Expense (+$)
Research Development20,224
Selling General Administrative4,898
Selling And Marketing Expenses0
Operating Expense29,05925,122
 
Net Interest Income (+$)
Interest Income42
Interest Expense-24
Other Finance Cost-0
Net Interest Income18
 
Pretax Income (+$)
Operating Income-29,059
Net Interest Income18
Other Non-Operating Income Expenses0
Income Before Tax (EBT)-28,355-29,059
EBIT - interestExpense = -29,137
-28,355
-28,132
Interest Expense24
Earnings Before Interest and Taxes (EBIT)-29,113-28,331
Earnings Before Interest and Taxes (EBITDA)-28,170
 
After tax Income (+$)
Income Before Tax-28,355
Tax Provision--199
Net Income From Continuing Ops-28,156-28,156
Net Income-28,156
Net Income Applicable To Common Shares-28,156
 
Non-recurring Events
Discontinued Operations0
Extraordinary Items0
Effect of Accounting Charges0
Other Items0
Non Recurring0
Other Operating Expenses19
Total Other Income/Expenses Net0-18
 

Technical Analysis of Vivoryon
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Vivoryon. The general trend of Vivoryon is BEARISH with 100.0% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Vivoryon's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (-100.0%) Bearish trend (100.0%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Vivoryon Therapeutics NV.

The long score for the Support & Resistance is 0/1.
The longshort score for the Support & Resistance is 0/(-1 +1).

  • Between support/resistance: The price is trading between support and resistance lines.

The bullish price targets are: 6.4 < 6.82 < 6.86.

The bearish price targets are: 0.49.

Tweet this
Vivoryon Therapeutics NV Daily Support & Resistance Chart

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Vivoryon Therapeutics NV. The current mas is .

The long score for the Moving Averages is 0/14.
The longshort score for the Moving Averages is -14/(-14 +14).

  • MA 20 trending down: The MA 20 is trending down. -1
  • Close < MA 20: The price is below the MA 20. -1
  • MA 20 < MA 50: The MA 20 is lower than the MA 50. -1
  • MA 20 < MA 100: The MA 20 is lower than the MA 100. -1
  • MA 20 < MA 200: The MA 20 is lower than the MA 200. -1
  • MA 50 trending down: The MA 50 is trending down. -1
  • Close < MA 50: The price is below the MA 50. -1
  • MA 50 < MA 100: The MA 50 is lower than the MA 100. -1
  • MA 50 < MA 200: The MA 50 is lower than the MA 200. -1
  • MA 100 trending down: The MA 100 is trending down. -1
  • Close < MA 100: The price is below the MA 100. -1
  • MA 100 < MA 200: The MA 100 is lower than the MA 200. -1
  • MA 200 trending down: The MA 200 is trending down. -1
  • Close < MA 200: The price is below the MA 200. -1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Vivoryon Therapeutics NV Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Vivoryon Therapeutics NV. The current macd is -1.57402063.

The long score for the Moving Average Convergence/Divergence (MACD) is 3/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is 2/(-4 +4).

  • MACD line > signal line: The MACD line is above the signal line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the Vivoryon price going up in the near term. +2
  • MACD < 0: The MACD is below the zero line (centerline), it indicates a bearish signal for Vivoryon. This means that the short-term moving average is lower than the long-term moving average, signaling negative momentum and suggesting a higher likelihood of the Vivoryon price continuing to fall in the near future. It indicates that sellers are gaining control, and there is negativism in the market, leading to potential price decreases. -1
  • Trending up: The MACD line is trending up. This indicates that the short-term moving average is rising faster than the long-term moving average, suggesting positive momentum in the market. This signals that buyers are becoming more active and confident, leading to potential price increases as traders anticipate further gains and are willing to buy at higher prices. +1
Vivoryon Therapeutics NV Daily Moving Average Convergence/Divergence (MACD) ChartVivoryon Therapeutics NV Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Vivoryon Therapeutics NV. The current adx is 64.04.

The long score for the Directional Movement Index (DMI) is 0/7.
The longshort score for the Directional Movement Index (DMI) is -4/(-7 +7).

  • PLUS_ID < MINUS_DI: The +DI line is below the -DI line. This indicates a bearish signal in the market, as the negative directional movement is currently stronger than the positive directional movement, showing that sellers have the upper hand. Market psychology suggests that traders are pessimistic, expecting further price decreases, and are more willing to sell Vivoryon shares, leading to potential downward momentum in its price. -1
  • PLUS_ID < MINUS_DI && ADX > 25 && ADX trending up: The ADX is above 25 and indicates a strong bearish trend. The ADX is trending up, so the bearish trend is strengthening.
Vivoryon Therapeutics NV Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Vivoryon Therapeutics NV. The current sar is 0.98343127.

The long score for the Parabolic SAR is 0/1.
The longshort score for the Parabolic SAR is -1/(-1 +1).

  • Close < SAR: The price is below the SAR. It's generally considered a bearish signal. -1
Vivoryon Therapeutics NV Daily Parabolic SAR Chart

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Vivoryon Therapeutics NV. The current rsi is 10.93. The current phase is Oversold in bear market.

The long score for the Relative Strength Index (RSI) is 2/13.
The longshort score for the Relative Strength Index (RSI) is 2/(-13 +13).

  • Oversold in bear market: Short-term excessive selling, potential for relief rally. Be cautious, consider taking short-term long positions. +1
  • Trending up: The RSI is trending up. +1
Vivoryon Therapeutics NV Daily Relative Strength Index (RSI) ChartVivoryon Therapeutics NV Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Vivoryon Therapeutics NV. The current phase is Continuation in bear market.

The long score for the Stochastic Oscillator is 3/6.
The longshort score for the Stochastic Oscillator is 2/(-6 +6).

  • STOCH < 50: The STOCH %K is below 50. There are more sellers than buyers. -1
  • STOCH %K line > STOCH %D line: The STOCH %K line is above the STOCH %D line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the Vivoryon price going up in the near term. +2
  • Trending up: The STOCH %K is trending up. +1
Vivoryon Therapeutics NV Daily Stochastic Oscillator ChartVivoryon Therapeutics NV Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Vivoryon Therapeutics NV. The current cci is -40.27565061.

Vivoryon Therapeutics NV Daily Commodity Channel Index (CCI) ChartVivoryon Therapeutics NV Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Vivoryon Therapeutics NV. The current cmo is -83.50213546.

The long score for the Chande Momentum Oscillator (CMO) is 0/1.
The longshort score for the Chande Momentum Oscillator (CMO) is -1/(-1 +1).

  • CMO < 0: The CMO is below 0, the momentum of the price is negative, indicating a potential downtrend in the price. -1
Vivoryon Therapeutics NV Daily Chande Momentum Oscillator (CMO) ChartVivoryon Therapeutics NV Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Vivoryon Therapeutics NV. The current willr is -75.

The long score for the Williams %R is 0/1.
The longshort score for the Williams %R is 0/(-1 +1).

  • WILLR between -80 and -20: The Williams %R is between -80 and -20. This indicates that Vivoryon is trading in a neutral price range, neither oversold nor overbought, suggesting a balanced market condition without any extreme price signals.
Vivoryon Therapeutics NV Daily Williams %R ChartVivoryon Therapeutics NV Daily Williams %R Chart

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of Vivoryon Therapeutics NV.

Vivoryon Therapeutics NV Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Vivoryon Therapeutics NV. The current atr is 0.28196512.

Vivoryon Therapeutics NV Daily Average True Range (ATR) ChartVivoryon Therapeutics NV Daily Average True Range (ATR) Chart

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Vivoryon Therapeutics NV. The current obv is -21,916,122.

Vivoryon Therapeutics NV Daily On-Balance Volume (OBV) ChartVivoryon Therapeutics NV Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Vivoryon Therapeutics NV. The current mfi is 62.87.

The long score for the Money Flow Index (MFI) is 1/2.
The longshort score for the Money Flow Index (MFI) is 1/(-2 +2).

  • MFI > 50: +1
Vivoryon Therapeutics NV Daily Money Flow Index (MFI) ChartVivoryon Therapeutics NV Daily Money Flow Index (MFI) Chart

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Vivoryon Therapeutics NV.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2023-11-08STOCH SHORT EXITThe %K line crosses above the %D line.
2023-11-09STOCH LONG EXITThe %K line crosses below the %D line.
2023-11-10WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2023-11-13STOCH SHORT EXITThe %K line crosses above the %D line.
2023-11-14ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-11-16STOCH LONG EXITThe %K line crosses below the %D line.
2023-11-20SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-11-21STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2023-11-23STOCH SHORT EXITThe %K line crosses above the %D line.
2023-11-24STOCH LONG EXITThe %K line crosses below the %D line.
2023-11-27DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
2023-11-28DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
2023-11-29DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
2023-11-30STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-01WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2023-12-04DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
2023-12-06STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-07STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2023-12-11STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-12STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-13STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-14DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-12-18STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-19STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2023-12-20BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2023-12-21STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-27STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2023-12-28STOCH LONG EXITThe %K line crosses below the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-01-02STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-03STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-01-04CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-01-05CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-01-08SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-01-09CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-01-10MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-01-11DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
2024-01-12STOCH SHORT EXITThe %K line crosses above the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-01-17STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-18DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-19DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-01-22STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-23MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-01-25WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-01-29RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-01CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-02-05MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-06CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-02-07STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-02-08STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-02-09MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-02-12STOCH LONG EXITThe %K line crosses below the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-02-14STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-02-16STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-21MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-02-22CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-02-23CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-02-26SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2024-02-28WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-02-29DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
2024-03-01STOCH SHORT EXITThe %K line crosses above the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-03-04STOCH LONG EXITThe %K line crosses below the %D line.
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-03-05MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-03-11STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-13STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-21STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-22MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2024-03-27STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-03-28STOCH SHORT EXITThe %K line crosses above the %D line.

6.3. Candlestick Patterns

Vivoryon Therapeutics NV Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Vivoryon Therapeutics NV based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5010.930
Ma 20Greater thanMa 500.980
Ma 50Greater thanMa 1005.699
Ma 100Greater thanMa 2006.762
OpenGreater thanClose0.524
Total0/5 (0.0%)
Penke

Good job! You gained 25 XP and 0   0   10 . What's next:

  • Share my analysis of Vivoryon with someone you think should read this too:
  • Are you bullish or bearish on Vivoryon? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Vivoryon? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Vivoryon Therapeutics NV

I send you an email if I find something interesting about Vivoryon Therapeutics NV.


Comments

How you think about this?

Leave a comment

Stay informed about Vivoryon Therapeutics NV.

Receive notifications about Vivoryon Therapeutics NV in your mailbox!